BioGend Therapeutics

BioGend Therapeutics Co.,Ltd.

BioGend Therapeutics, a regenerative engineering company, focuses on the development of advanced biologic products for bone and joint repair and restoration.

Latest News

22 September

News Releases

Osteo-Pharma (the licensor of OIF in Japan) has enrolled the first patient for the phase I/II clinical trial of OIF-contained beta-tricalcium phosphate in patients requiring alveolar bone augmentation before dental implant treatment.

Osteo-Pharma (the licensor of OIF in Japan) has enrolled the first patient for the phase I/II clinical trial of OIF-contained beta-tricalcium phosphate in patients requiring alveolar bone augmentation before dental implant treatment.

25 August

News Releases

04 August

News Releases

18 May

News Releases

BioGend submitted Investigational Device Exemption (“IDE”) application to U.S. FDA

BioGend submitted Investigational Device Exemption (“IDE”) application to U.S. FDA for a feasibility study

22 April

News Releases

BioGend submitted the application for importing permit of 「“RevoCart” One-Step Autologous Cartilage Repair System」to China National Medical Products Administration.

01 February

News Releases

“RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from USPTO.

“RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from USPTO.

19 January

News Releases

The Investigational Device Exemption (IDE) of BiG001 with an indication of bone graft for treatment of open tibial fracture was conditional approved by US FDA

The Investigational Device Exemption (IDE) of BiG001 with an indication of bone graft for treatment of open tibial fracture was conditional approved by US FDA

06 January

News Releases

Biogend acquired self-paid price for RevoCart one-step autologous cartilage repair system.

Biogend acquired self-paid price for RevoCart one-step autologous cartilage repair system.

22 December

News Releases

BioGend submitted the Investigational Device Exemption (IDE) of BiG001 with an indication of bone graft for treatment of open tibial fractures, a feasibility study, to USFDA.

16 December

News Releases

BioGend Therapeutics Co., Ltd. (stock code: 6733) held a performance presentation before stock listing on December 22, 2020

Products and Projects

Innovative Clinical Treatments

Particulate Autologous Cartialge Implantatiion (PACI)

No need for in-vitro cell culture

One-Step arthroscopic surgery

Fast and safe

Biologic Bone Graft

Bone grafting is a surgical procedure that replaces missing bone in order to repair bone fractures. The biological mechanism involved in bone grafting include osteoconduction, osteoinduction, and osteogenesis.

4F, No. 3, Park Street, Nangang District, Taipei 115

info@biogend.com.tw

+886-2-2655-8366 Customer Service Telephone Number:0911-886-733

© 2019 BioGend Therapeutics Co.,Ltd. All rights reserved. 網頁設計 - 好點子數位創意